[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340688-105":59,"doc-detail-340688-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","innovative-strategies-tooptimise-colorectal-cancer-immunotherapy-through-molecular-mechanism-insights","Innovative strategies tooptimise colorectal cancer immunotherapy through molecular mechanism insights","","Innovative strategies focus on colorectal cancer (CRC), where tumor microenvironment heterogeneity and diverse tumor cell states shape patient outcomes and treatment response. Single-cell RNA sequencing was applied to 13 tissue samples from 4 CRC patients to define key tumor microenvironment cell types and map intercellular communication using CellChat. A risk score model based on eight prognostic genes enabled stratification for immunotherapeutic suitability. In vitro validation of DLX2 supported its role as a critical target, informing drug-sensitivity enhancement and therapeutic optimization for improved CRC survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/innovative-strategies-tooptimise-colorectal-cancer-immunotherapy-through-molecular-mechanism-insights/340688/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/innovative-strategies-tooptimise-colorectal-cancer-immunotherapy-through-molecular-mechanism-insights/340688.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and technologies were used to study colorectal cancer in this work?","Question",{"text":112,"@type":113},"The study used single-cell RNA sequencing on 13 CRC tissue samples from 4 patients, and evaluated intercellular communication with CellChat. In vitro experiments were also conducted to test DLX2’s function in CRC progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was patient risk stratification for immunotherapy achieved?",{"text":117,"@type":113},"A risk score model was built using eight prognostic genes. This model was used to classify patients and predict survival outcomes at 1, 3, and 5 years.",{"name":119,"@type":110,"acceptedAnswer":120},"Which tumor cell subtype and gene were highlighted as clinically relevant?",{"text":121,"@type":113},"The C0 FXYD5+ tumor cell subtype was linked to cancer progression and poor prognosis. DLX2 was validated as a critical gene associated with poor prognosis, supporting its potential as a therapeutic target.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340688,1790640336,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","TYPE Original Research PUBLISHED 09 December 2024 DOI 10.3389/fimmu.2024.1509658  \nOPEN ACCESS  \nEDITED BY  \nQi Zhang,  \nYale University, United States  \nREVIEWED BY  \nBufu Tang,  \nFudan University, China Yihang Qi,  \nHarvard Medical School, United States Ximing Ran,  \nEmory University, United States Weihao Zhao,  \nYale University, United States  \n*CORRESPONDENCE  \nYihang Yuan  \n [surgeryuan@outlook.com](surgeryuan@outlook.com)[ ](surgeryuan@outlook.com)Peng Sun  \n [sp2082@shtrhospital.com](sp2082@shtrhospital.com)[ ](sp2082@shtrhospital.com)Xinyi Zhang  \n [2249317206@qq.com](2249317206@qq.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 11 October 2024  \nACCEPTED 21 November 2024  \nPUBLISHED 09 December 2024  \nCITATION  \nLin Q, Wang Z, Wang J, Xu M, Zhang X, Sun P and Yuan Y (2024) Innovative strategies tooptimise colorectal cancer immunotherapy through molecular mechanism insights.  \nFront. Immunol. 15:1509658 .  \ndoi: 10.3389/fimmu.2024.1509658  \nCOPYRIGHT  \n© 2024 Lin, Wang, Wang, Xu, Zhang, Sun and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nInnovative strategies tooptimise colorectal cancer immunotherapy through molecular mechanism insights  \nQuanjun Lin 1†, Zhiqiang Wang 1†, Jue Wang 1, Ming Xu 1, Xinyi Zhang 2*, Peng Sun 1* and Yihang Yuan 1*  \n1 Department of General Surgery, Tongren Hospital, Shanghai Jiao Tong University School of  \nMedicine, Shanghai, China, 2Clinical Medical College, Southwest Medical University, Luzhou, China  \nBackground: Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally. The heterogeneity of the tumor microenvironment signiﬁcantly inﬂuences patient prognosis, while the diversity of tumor cells shapes its unique characteristics. A comprehensive analysis of the molecular proﬁle of tumor cells is crucial for identifying novel molecular targets for drug sensitivity analysis and for uncovering the pathophysiological mechanisms underlying CRC.  \nMethods: We utilized single-cell RNA sequencing technology to analyze 13 tissue samples from 4 CRC patients, identifying key cell types within the tumor microenvironment. Intercellular communication was assessed using CellChat, and a risk score model was developed based on eight prognostic genes to enhance patient stratiﬁcation for immunotherapeutic approaches. Additionally, in vitro experiments were performed on DLX2, a gene strongly associated with poor prognosis, to validate its potential role as a therapeutic target in CRC progression.  \nResults: Eight major cell types were identiﬁed across the tissue samples. Within the tumor cell population, seven distinct subtypes were recognized, with the C0 FXYD5+ tumor cells subtype being signiﬁcantly linked to cancer progression and poor prognosis. CellChat analysis indicated extensive communication among tumor cells, ﬁbroblasts, and immune cells, underscoring the complexity of the tumor microenvironment. The risk score model demonstrated high accuracy in predicting 1-, 3-, and 5-year survival rates in CRC patients. Enrichment analysis revealed that the C0 FXYD5+ tumor cell subtype exhibited increased energy metabolism, protein synthesis, and oxidative phosphorylation, contributing to its aggressive behavior. In vitro experiments conﬁrmed DLX2 as a critical gene associated with poor prognosis, suggesting its viability as a target for improving drug sensitivity.  \nConclusion: In summary, this study advances our understanding of CRC progression by identifying critical tumor subtypes, molecular pathways, and  \nFrontiers in Immunology 01 [","cbCaiaHeShLKqg9Y","https://ap.wps.com/l/cbCaiaHeShLKqg9Y","pdf",12945762,24,"English","# 1 Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What data and technologies were used to study colorectal cancer in this work?\",\"answer\":\"The study used single-cell RNA sequencing on 13 CRC tissue samples from 4 patients, and evaluated intercellular communication with CellChat. In vitro experiments were also conducted to test DLX2’s function in CRC progression.\"},{\"question\":\"How was patient risk stratification for immunotherapy achieved?\",\"answer\":\"A risk score model was built using eight prognostic genes. This model was used to classify patients and predict survival outcomes at 1, 3, and 5 years.\"},{\"question\":\"Which tumor cell subtype and gene were highlighted as clinically relevant?\",\"answer\":\"The C0 FXYD5+ tumor cell subtype was linked to cancer progression and poor prognosis. DLX2 was validated as a critical gene associated with poor prognosis, supporting its potential as a therapeutic target.\"}]","Innovative strategies tooptimise colorectal cancer immunotherapy through molecular mechanism insights | PDF",1790038208,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ab935925abd35c9357c66b4cb2d367b.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16f51985ee6c2b7be566fd0c59638364.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f8cafa1d56d4fdea8709886627dd6c2.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5de3060d80d1be0eabd262e2720f064f.webp",980,1385]